Breckenridge Pharmaceutical Inc. announced a voluntary, nationwide recall of one lot of 60 mg propranolol hydrochloride extended‑release capsules (lot PK25110035, expiration May 2029). The medication, commonly prescribed to treat high blood pressure and certain heart conditions, was distributed to wholesalers and pharmacies across the United States between Oct. 26, 2026 and Nov. 4, 2026.
Reason for the recall
The company said the affected lot shared intermediate material that is suspected to be the source of metal contamination identified in a separate, unreleased lot. While no adverse events have been reported that are linked to this recall, the company warned that use of the product could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine.
What patients should do
Consumers who may have received the recalled capsules are instructed to stop using the medication immediately. They should contact their doctor or other healthcare provider for medical advice and instructions on obtaining a replacement. Unused medication should be returned to the pharmacy where it was originally picked up.
Breckenridge also urged wholesalers, pharmacies and other retailers to check their inventories and remove any remaining stock of the affected lot.
About propranolol
According to the Cleveland Clinic, propranolol hydrochloride extended‑release capsules help manage high blood pressure and heart disease by lowering blood pressure and heart rate, making it easier for the heart to pump blood throughout the body. The medication is a beta‑blocker and has been a mainstay in cardiovascular therapy for decades.
Safety and regulatory context
Recalls of pharmaceutical products, while uncommon, are an important safety mechanism to protect patients. The Food and Drug Administration (FDA) works closely with manufacturers to ensure that any potential contamination or defect is addressed promptly. In this case, Breckenridge’s proactive voluntary recall demonstrates a commitment to patient safety and regulatory compliance.
Patients who have concerns about their blood‑pressure medication should not discontinue treatment without consulting a healthcare professional. Alternative therapies or temporary substitutions may be available while the recalled product is removed from the market.
What’s next?
Breckenridge Pharmaceutical has indicated that it is investigating the source of the contamination and will provide updates as more information becomes available. The company has not announced any changes to other product lines or future manufacturing processes at this time.
For the latest information, patients and providers can visit Breckenridge’s website or contact the company’s consumer safety hotline.
Original reporting: 40/29 / KHBS (NW Arkansas) — read the source article.